Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Johnson

Showing results (121-130 of 152) with videos related to

Pageof 16
Sort By:
Cancer Research|November 13, 2020
Replication Gaps Underlie BRCA Deficiency and Therapy ResponseNicholas J Panzarino, John J Krais, Ke Cong, et al.
Molecular Cell|June 3, 2021
ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemiaDaniela Di Marcantonio, Esteban Martinez, Joice S Kanefsky, et al.
Contemporary Clinical Trials|April 10, 2022
Defining optimal treatment for recurrent Clostridioides difficile infection (OpTION study): A randomized, double-blind comparison of three antibiotic regimens for patients with a first or second recurrenceStuart Johnson, Dale N Gerding, Xue Li, et al.
Molecular Cell|July 3, 2021
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiencyKe Cong, Min Peng, Arne Nedergaard Kousholt, et al.
Molecular Cell|August 6, 2021
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiencyKe Cong, Min Peng, Arne Nedergaard Kousholt, et al.
Nature Communications|July 9, 2024
FAM122A ensures cell cycle interphase progression and checkpoint control by inhibiting B55α/PP2A through helical motifsJason S Wasserman, Bulat Faezov, Kishan R Patel, et al.
Scientific Reports|June 28, 2018
Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicingSarah V Gerhart, Wendy A Kellner, Christine Thompson, et al.
Molecular Cancer Therapeutics|October 3, 2019
Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion MutationsPyoung Hwa Park, Tomomi M Yamamoto, Hua Li, et al.
Nature Medicine|June 28, 2011
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibitionNeil Johnson, Yu-Chen Li, Zandra E Walton, et al.
Cancer Research|February 18, 2021
Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End JoiningQin Zhou, Michelle E Howard, Xinyi Tu, et al.
Pageof 16

Showing results (121-130 of 152) with videos related to

Sort By:
Pageof 16
Cancer Research|November 13, 2020
Replication Gaps Underlie BRCA Deficiency and Therapy ResponseNicholas J Panzarino, John J Krais, Ke Cong, et al.
Molecular Cell|June 3, 2021
ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemiaDaniela Di Marcantonio, Esteban Martinez, Joice S Kanefsky, et al.
Contemporary Clinical Trials|April 10, 2022
Defining optimal treatment for recurrent Clostridioides difficile infection (OpTION study): A randomized, double-blind comparison of three antibiotic regimens for patients with a first or second recurrenceStuart Johnson, Dale N Gerding, Xue Li, et al.
Molecular Cell|July 3, 2021
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiencyKe Cong, Min Peng, Arne Nedergaard Kousholt, et al.
Molecular Cell|August 6, 2021
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiencyKe Cong, Min Peng, Arne Nedergaard Kousholt, et al.
Nature Communications|July 9, 2024
FAM122A ensures cell cycle interphase progression and checkpoint control by inhibiting B55α/PP2A through helical motifsJason S Wasserman, Bulat Faezov, Kishan R Patel, et al.
Scientific Reports|June 28, 2018
Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicingSarah V Gerhart, Wendy A Kellner, Christine Thompson, et al.
Molecular Cancer Therapeutics|October 3, 2019
Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion MutationsPyoung Hwa Park, Tomomi M Yamamoto, Hua Li, et al.
Nature Medicine|June 28, 2011
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibitionNeil Johnson, Yu-Chen Li, Zandra E Walton, et al.
Cancer Research|February 18, 2021
Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End JoiningQin Zhou, Michelle E Howard, Xinyi Tu, et al.
Pageof 16